All these ann and still no movement, page-3

"earnings call"? LOL.
We are a drug development company in the early stages of introducing a novel product that has high potential but also significant marketing costs; and as a novel product, we can expect a long runway to achieving its full sales potential - and that's just in Singapore. So you will need to evaluate the future prospects of our company somewhat qualitatively and not based on EPS - at least for the time being. FYI, our 4C at 30 September reported sales of $17k. I'm sure they will improve in the December quarter with the HCP marketing starting in Singapore, but let's not set ourselves up for disappointment by expecting profits, just yet.